Summary
Desmopressin is a widely used hemostatic drug. It is a synthetic analogue of the natural hormone vasopressin, but, in contrast to vasopressin, it has no pressor activity. The effect is immediate, with two- to sixfold increases in the plasma concentrations of coagulation factor VIII, on Willebrand factor, and tissue plasminogen activator, and increases in platelet adhesiveness of comparable magnitude. Desmopressin is used in patients with mild hemophilia A, von Willebrand's disease, congenital platelet dysfunction, or acquired platelet dysfunction due to uremia or intake of such drugs as aspirin. It may also be used to reduce surgical blood loss in patients without known bleeding diathesis. Optimal hemostatic effect is achieved with a dosage of 0.3 μg/kg given intravenously. Other routes of administration are subcutaneous injection or intranasal spray. The latter proved to be efficient for home treatment of patients with bleeding disorders.
Similar content being viewed by others
References
Zaoral M, Kolc J, Sorm F (1967) Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-d-amino-butyrine vasopressin, 1-deamino-8-d-lysine vasopressin and 1-deamino-8-d-arginine vasopressin. Collection Czechoslov. Chem Commun 32:1250–1257
Walter R (1976) Partial purification and characterization of post-proline cleaving enzyme: enzymatic inactivation of neu-rohypophysial hormones by kidney preparations of various species. Biochim Biophys Acta 422:138–158
Shimizu K, Hoshine M, Kumagawa J et al (1980) Mechanism of the prolonged antidiuretic action of DDAVP and its metabolic features. In: Share L, Yoshida S, Yagi K (eds) Antidiuretic hormone. University Park Press, Baltimore, pp 271–284
Ingram GIC (1961) Increase in antihaemophilic globulin activity following infusion of adrenaline. J Physiol 156:217–224
Egeberg O (1963) Changes in the activity of antihemophilic A factor (f.VIII) and in the bleeding time associated with muscular exercise and adrenaline infusion. Scand J Clin Lab Invest 15:539
Schneck S, von Kaulla KN (1961) Fibrinolysis and the nervous system. Neurology (Minneapolis) 11:959
Mannucci PM, Gagnatelli G, D'Alonzo R (1972) Stress and blood coagulation. In: Brinkhous KM, Hinnom S (eds) Thrombosis: risk factors and diagnostic approaches. Schattauer, Stuttgart, pp 105–1
Cash JD, Gader AMA, Da Costa J (1974) The release of plasminogen activator and factor VIII by LVP, AVP, DDAVP, AT III and OT in man. Br J Haematol 27:363–364
Mannucci PM, Åberg M, Nilsson IM, Robertsson B (1975) Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 30:81–93
Åberg M, Nilsson IM, Vilhardt H (1979) The release of fibrinolytic activator and factor VIII after injection of DDAVP. In: Davidsson JF (ed) Progress in chemical fibrinolysis and thrombolysis. Churchill Livingstone, Edinburgh, pp 92–97
Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977) 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's disease. Lancet 1:869–872
Kobayashi I (1979) Treatment of hemophilia A and von Willebrand's disease patients with an intranasal dripping of DDAVP. Thromb Res 16:775–779
Nilsson IM, Holmberg L, Åberg M, Vilhardt H (1980) The release of plasminogen activator and factor VIII after injection of DDAVP in healthy volunteers and in patients with von Willebrand's disease. Scand J Haematol 24:351–359
Nilsson IM, Vilhardt H, Holmberg L, Åstedt B (1982) Association between factor VIII related antigen and plasminogen activator. Acta Med Scand 211:105–1
Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977) DDAVP in haemophilia. Lancet 2:1171–1172
Kobrinsky NL, Doyle JJ, Israels EDS et al (1985) Absent factor VIII response to synthetic vasopressin analogue in nephrogenic diabetes insipidus. Lancet 1:1293–1294
Bichet DG, Razzi M, Lonergan M et al (1988) Hemodynamic and coagulation responses to 1-desamino[8-d-arginine]vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 318:881–887
Brenner B, Seligsohn U, Hochberg Z (1988) Normal response of factor VIII and von Willebrand factor to 1-deamino-8-d-arginine vasopressin in nephrogenic diabetes insipidus. J Clin Endocrin Metabol 67:191–193
Ohzeki T, Sunaguchi M, Tsunei M, Shinzawa T, Hanaki K, Shiraki K, Shishido H (1988) Coagulation factor responsiveness in nephrogenic diabetes insipidus. J Pediatrics 113:790
Schwartz J (1989) Vasodilation associated with V2-type vasopressin activity: findings and implications. Moll Cell Endocrinol 64:133–136
Hashemi S et al (1990) DDAVP-induced release of von Willebrand factor from endothelial cells in vitro; the effect of plasma and blood cells. Biochim Biophys Acta 1052:63–70
Macia RA, Silver AC, Gabel RA, Campbell GK, Hanna N, DiMartino MJ (1990) Hypotension induced by vasopressin antagonists in rats: role of mast cell degranulation. Toxicol Appl Pharmacol 102:117–127
Johns RA (1990) Desmopressin is a potent vasorelaxant of aorta and pulmonary artery isolated from rabbi and rat. Anesthesiology 72:858–864
Murphy DJ, Joran ME (1992) Respiratory and cardiovascular changes associated with toxic doses of a peptide antagonist of vasopressin in the rat. Fundam Appl Toxicol 18:307–313
Mannuci PM (1986) Desmopressin (DDAVP) for treatment of disorders of hemostasis. In: Coller BS (ed) Progress in hemostasis and thrombosis. Grune & Stratton, Orlando, pp 19–45
Nilsson IM, Mikaelsson M, Vilhardt H (1982) The effect of intranasal DDAVP on coagulation and fibrinolytic activity in normal persons. Scand J Haematol 29:70–74
Stel HV, van der Kwast ThH, Veerman ECI (1983) Detection of factor VIII/coagulant antigen in human liver-tissue. Nature 303:530–532
Wion KL, Kelly D, Summerfield JA, Tuddenham EGD, Lawn RM (1985) Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 317:726–729
Zelechowska MG, van Mourik JA, Brodniewicz-Porba T (1985) Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes. Nature 317:729–730
Howard MA, Montgomery DC, Hardisty RM (1974) Factor VIII-related antigen in platelets. Thromb Res 4:617–624
Nachmann RL, Jaffe EA (1975) Subcellular platelet factor VIII antigen and von Willebrand factor. J Exp Med 141:1101–1103
Booyse FM, Osikowicz G, Feder S (1981) Effects of various agents on ristocetin-Willebrand factor activity in long-term cultures of von Willebrand and normal human umbilical vein endothelial cells. Thromb Haemost 46:668
Tuddenham EGD, Lane RS, Rotblat F et al (1982) Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol 52:259–267
Weiss HJ, Baumgartner HR, Tschopp TB, Turitto VT, Cohen D (1978) Correction by factor VIII of the impaired platelet adhesion to subendothelium in von Willebrand disease. Blood 51:267–279
Sakariassen KS, Cattaneo M, van den Berg A, Ruggeri ZM, Mannucci PM, Sixma JJ (1984) DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 64:229–236
Lethagen S, Nilsson IM (1992) DDAVP-induced enhancement of platelet retention. Its dependence on plateletvon Willebrand factor and the platelet receptor GPIIb/IIIa. Eur J Haematol 49:7–13
Lethagen S, Rugarn P (1992) The effect of DDAVP and placebo on platelet function and prolonged bleeding time induced by oral acetylsalicylic acid treatment in healthy volunteers. Thromb Haemost 67:185–186
Mannuci PM, Canciani MT, Rota L, Donovan BS (1981) Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects, and patients with haemophilia A and von Willebrand's disease. Br J Haematol 47:283–293
Lethagen S, Harris AS, Sjörin E, Nilsson IM (1987) Intranasal and intravenous administration of desmopressin: effect on f VIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 58:1033–1036
Köhler M, Hellstern P, Miyashita C, von Blohm G, Wenzel E (1986) Comparative study of intranasal, subcutaneous and intravenous administration of desamino-d-arginine vasopressin (DDAVP). Thromb Haemost 55:108–111
Köhler M, Mariani G (1993) Intravenous and subcutaneous desmopressin: clinical results. In: Mariani G, Mannucci PM, Cattaneo M (eds) Desmopressin in bleeding disorders. Plenum, New York, 309–316
Harris AS, Nilsson IM, Wagner ZG, Alkner U (1986) Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin. J Pharm Sci 75:1085–1088
Harris AS, Ohlin M, Lethagen S, Nilsson IM (1988) Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. J Pharm Sci 77:337–339
Nilsson IM, Felding P, Timberg L, Jonsson S, Harris AS (1986) Clinical experience with DDAVP. In: Ciavarella NL, Ruggeri Z, Zimmerman TS (eds) Factor VIII/von Willebrand factor. Biological and clinical advances. Proceedings of Bari Int Conference. Wichtig, Milano, pp 63–80
Mannucci PM, Vicente V, Alberca I, Sacchi E, Longo G, Harris AS, Lindquist A (1987) Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Thromb Haemost 58:1037–1039
Ghirardini A, Mariani G, Iacopino G, Tirindelli MC, Solinas S, Moretti T (1987) Concentrated DDAVP: further improvement in the management of mild factor VIII deficiencies. Thromb Haemost 58:896–989
Lethagen S, Harris AS, Nilsson IM (1990) Intranasal desmopressin (DDAVP) by spray in mild haemophilia A and von Willebrand's disease type I. Blut 60:187–191
Mannucci PM, Lombardi R, Bader R et al (1985) Heterogeneity of type-I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood 66:796–802
Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS (1982) Multimeric composition of factor VIII/ von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrands disease subtypes. Blood 59:1272–1278
Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjörin E (1983) Platelet aggregation induced by 1-deamino-8-d-arginine vasopressin (DDAVP) in type IIB von Willebrand's disease. N Engl J Med 309:816–821
Gralnick HR, William SB, McKeown LP, Rick ME, Maissonneuve P, Jenneau C, Sultan Y (1986) DDAVP in type IIa von Willebrand's disease. Blood 67:465–468
Holmberg L, Nilsson IM (1992) Von Willebrand's disease. Eur J Haematol 48:127–141
Kobrinsky NL, Israels ED, Gerrard JM et al (1984) Shortening of the bleeding time by 1-deamino-8-d-arginine vasopressin in various bleeding disorders. Lancet 1:1145–1148
Winckelman G, Augustin R (1985) Improvement of primary hemostasis by DDAVP in patients with various platelet defects. Thromb Haemost 54:12
Marti GE, Rick ME, Sidbury U, Gralnick HR (1986) DDAVP infusion in five patients with type Ia glycogen storage disease and associated correction of prolonged bleeding times. Blood 68:180–184
Mannucci PM, Vicente V, Vianello L et al (1986) Controlled trial of desmopressin in liver cirrhosis and other conditions associated with prolonged bleeding time. Blood 67:1148–1153
Schulman S, Johnsson H, Egberg N, Blombäck M (1987) DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thromb Res 45:165–174
Kentro TB, Lottenberg R, Kitchens CS (1987) Clinical efficacy of desmopressin acetate for hemostatic control in patients with primary platelet disorders undergoing surgery. Am J Hematol 24:215–219
DiMichele DM, Hathaway WE (1990) Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 33:39–45
Kim HC, Salva KS, Fallot PL et al (1988) Patients with prolonged bleeding time of undefined etiology, and their response to desmopressin. Thromb Haemost 59:221–224
Nilsson IM, Lethagen S (1991) Current status of DDAVP formulations and their use. In: Lusher JM, Kessler CM (eds) Hemophilia and von Willebrand's disease in the 1990s. Elsevier Science, Amsterdam, pp 443–453
Schulman S, Johnsson H (1991) Heparin, DDAVP and the bleeding time. Thromb Haemost 65:242–244
Lethagen S, Rugarn P, Åberg M, Nilsson IM (1990) Effects of desmopressin acetate (DDAVP) and dextran on hemostatic and thromboprophylactic mechanisms. Acta Chir Scand 156:597–602
Jansson PA, Jubelirer SJ, Weinstein MS, Deykin D (1980) Treatment of bleeding tendency in uremia with cryoprecipitate. N Engl J Med 303:1318–1322
Watson AJS, Koegh JAB (1982) Effect of 1-deamino-8-d-arginine vasopressin on the prolonged bleeding time in chronic renal failure. Nephron 32:49–52
Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, Zimmerman TS (1983) Deamino-8-d-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 308:8–12
Shapiro MD, Kelleher SP (1984) Intranasal 1-deamino-8-d-arginine vasopressin shortens the bleeding time in uremia. Am J Neophrol 4:260–261
Agnelli G, Berretini M, Cunto MD, Nenci GG (1983) Desmopressin-induced improvement of abnormal coagulation in chronic liver disease. Lancet 1:645
Burrhoughs AK, Matthews K, Quadiri M et al (1985) Desmopressin and bleeding time in patients with cirrhosis. Br Med J 291:1377–1381
Rose EH, Aledort LM (1991) Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 114:563–568
Lethagen S, Ragnarson-Tenvall G (1993) Self-treatment with desmopressin intranasal spray in patients with bleeding disorders. Effect on bleeding symptoms and socioeconomic factors. Ann Hematol 66:257–260
Lowe G, Pettigrew A, Middleton S, Frobes CD, Prentice CRM (1977) DDAVP in haemophilia. Lancet 2:614–615
Theiss W, Schmidt G (1978) DDAVP and von Willebrand disease: repeated administration and the behaviour of the bleeding time. Thromb Res 13:1119–1123
Mannucci PM, Bettega D, Cattaneo M (1992) The development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 82:87–93
Salzman EW, Weinstein MJ, Weintraub RM et al (1986) Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 314:1402–1406
Kobrinsky NL, Letts RM, Patel LR, Israels ED, Monson RC, Schweiz N, Cheang MS (1987) 1-Desamino-8-d-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial. Ann Intern Med 107:446–450
Rocha E, Llorens R, Paramo JA, Arcas R, Cuesta B, Trenor AM (1988) Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass? Circulation 77:1319–1323
Hackman T, Gascoyne RD, Naiman SC et al (1989) A trial of desmopressin (1-desamino-8-d-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med 321:1437–1443
Lazenby WD, Russo I, Zadeh BJ, Zelano JA, Ko W, Lynch CC, Isom OW, Krieger KH (1990) Treatment with desmo-pressin acetate in routine artery bypass surgery to improve postoperative hemostasis. Circulation 82 [Suppl IV]: 413–419
Lo Cicero J, Massad M, Matano J (1991) Effect of desmopressin acetate on hemorrhage without identifiable cause in coronary bypass patients. Am Surg 57:165–168
Horrow JC, van Riper DF, Strong MD, Brodsky I, Parmet JL (1991) Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 84:2063–2070
Guay J, Reinberg C, Rivard GE, Poitras B, Mathews S, David M (1990) DDAVP does not reduce bleeding during spinal fusion for idiopathic scoliosis. Can J Anaesth 37:14
Cattaneo M, Mannucci PM (1993) Desmopressin and blood loss after cardiac surgery. Lancet 342:812
Czer LSC, Bateman TM, Gray RJ et al (1987) Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin. JACC 9:1139–1147
Mongan PD, Hosking MP (1992) The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 77:38–46
Gratz I, Koehler J, Olsen D et al (1992) The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. J Thorac Cardiovasc Surg 104:1417–1422
Triplett DA (1989) Editorial: The bleeding time: neither pariah nor panacea. Arch Pathol Lab Med 113:1207–1208
Mikaelsson M, Nilsson IM, Vilhardt H, Wiechel B (1982) Factor VIII concentrate prepared from blood donors stimulated by intranasal administration of a vasopressin analogue. Transfusion 22:229–233
Palmer DS, Harris AS, Tittley P, Rock G (1988) Effectiveness, specificity and safety of intranasal 1-deamino-8-d-arginine vasopressin treatment of normal blood donors. Haemostasis 18:187–196
Mannucci PM (1988) Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 72:1449–1455
Koskimies O, Pylkkänen J, Vilska J (1984) Water intoxication in infants caused by the urine concentration test with vasopressin analogue (DDAVP). Acta Paediatr Scand 73:131–132
de la Fuente B, Kasper CK, Rickles FR, Hoyer LW (1985) Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. Ann Intern Med 103:6–14
Sheperd LL, Hutchinson RJ, Worden EK, Koopman CF, Coran A (1989) Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis. J Pediatr 114:470–472
Weinstein RE, Bona RD, Altman AJ, Quinn JJ, Weisman SJ, Bartolomeo A, Rickles FR (1989) Severe hyponatremia after repeated intravenous administration of desmopressin. Am J Hematol 32:258–261
Smith TJ, Gill JC, Ambrosu DR, Hathaway WE (1989) Hyponatremia and seizures in young children given DDAVP. Am J Hematol 31:199–202
Salvatoni A, Maghnie M, Lorini R, Marni E (1990) Hyponatremia and seizures during desmopressin acetate treatment in hypothyroidism. J Pediatr 116:835–836
Binch LJC, Jacobsen MB (1992) Hyponatremia in the treatment of von Willebrand's disease (in Norwegian). Tidsskr Nor Laegeforen 112:3670–3671
Beach PS, Beach RE, Smith LR (1992) Hyponatremic seizures in a child treated with desmopressin to control enuresis. A rational approach to fluid intake. Clin Pediatr Phila 31:566–569
Yaouyanc G, Jonville AP, Yaouyanc-Lapalle H, Barbier P, Dutertre JP, Autret E (1992) Seizure with hyponatremia in a child prescribed desmopressin for nocturnal enuresis. J Toxicol Clin Toxicol 30:637–641
Humphries KE, Siragy H (1993) Significant hyponatremia following DDAVP administration in a healthy adult. Am J Hematol 44:12–15
O'Brien JR, Green PJ, Salmon G et al (1989) Desmopressin and myocardial infarction. Lancet 1:664
van Dantzig JM, Duren DR, ten Cate JW (1989) Desmopressin and myocardial infarction. Lancet 1:664
Bond L, Bevan DU (1988) Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 318:121
Mannucci PM, Lusher JM (1989) Desmopressin and thrombosis. Lancet 2:675–676
Mannucci PM, Carlsson S, Harris AS (1994) Desmopressin, surgery and thrombosis. Thromb Haemost 71:154–155
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lethagen, S. Desmopressin (DDAVP) and hemostasis. Ann Hematol 69, 173–180 (1994). https://doi.org/10.1007/BF02215950
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02215950